Free Trial
NASDAQ:LAB

Standard BioTools (LAB) Stock Price, News & Analysis

Standard BioTools logo
$1.34 -0.03 (-1.82%)
Closing price 07/3/2025 03:36 PM Eastern
Extended Trading
$1.34 0.00 (0.00%)
As of 07/3/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Standard BioTools Stock (NASDAQ:LAB)

Key Stats

Today's Range
$1.31
$1.39
50-Day Range
$0.92
$1.37
52-Week Range
$0.92
$2.41
Volume
860,377 shs
Average Volume
1.95 million shs
Market Capitalization
$510.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50
Consensus Rating
Moderate Buy

Company Overview

Standard BioTools Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

LAB MarketRank™: 

Standard BioTools scored higher than 71% of companies evaluated by MarketBeat, and ranked 312th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Standard BioTools has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Standard BioTools has received no research coverage in the past 90 days.

  • Read more about Standard BioTools' stock forecast and price target.
  • Earnings Growth

    Earnings for Standard BioTools are expected to grow in the coming year, from ($0.29) to ($0.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Standard BioTools is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Standard BioTools is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Standard BioTools has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Standard BioTools' valuation and earnings.
  • Percentage of Shares Shorted

    4.42% of the float of Standard BioTools has been sold short.
  • Short Interest Ratio / Days to Cover

    Standard BioTools has a short interest ratio ("days to cover") of 9.8.
  • Change versus previous month

    Short interest in Standard BioTools has recently decreased by 5.16%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Standard BioTools does not currently pay a dividend.

  • Dividend Growth

    Standard BioTools does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.42% of the float of Standard BioTools has been sold short.
  • Short Interest Ratio / Days to Cover

    Standard BioTools has a short interest ratio ("days to cover") of 9.8.
  • Change versus previous month

    Short interest in Standard BioTools has recently decreased by 5.16%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Standard BioTools has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Standard BioTools this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for LAB on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Standard BioTools insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $57,451.00 in company stock.

  • Percentage Held by Insiders

    23.16% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Standard BioTools' insider trading history.
Receive LAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter.

LAB Stock News Headlines

Illumina to Buy SomaLogic for Up to $425 Mln
Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly positioned to fill it…
See More Headlines

LAB Stock Analysis - Frequently Asked Questions

Standard BioTools' stock was trading at $1.75 at the start of the year. Since then, LAB stock has decreased by 23.1% and is now trading at $1.3450.

Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Standard BioTools investors own include American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Today
7/05/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:LAB
Employees
620
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$2.50
Low Stock Price Target
$2.50
Potential Upside/Downside
+85.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$138.88 million
Pretax Margin
-78.07%

Debt

Sales & Book Value

Annual Sales
$174.43 million
Price / Cash Flow
N/A
Book Value
$1.27 per share
Price / Book
1.06

Miscellaneous

Free Float
291,855,000
Market Cap
$510.86 million
Optionable
Optionable
Beta
1.54
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:LAB) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners